The SPARK multi‑cohort Phase II trial reported activity for the combination of sitravatinib and tislelizumab in locally recurrent or metastatic triple‑negative breast cancer (TNBC). The single‑arm study showed objective responses in portions of an otherwise hard‑to‑treat population and provided cohort‑level safety profiling. Investigators highlighted the regimen’s immune‑modulating rationale—sitravatinib targets the tumor microenvironment while tislelizumab acts as PD‑1 blockade—supporting further evaluation in controlled trials and potential biomarker‑guided development.